VYNE Therapeutics (VYNE) stock
VYNE · VYNE Therapeutics Inc. · NASDAQ
What is the latest news on VYNE stock?
INSIDERago
Chief Development Officer Payton Lori was granted 99,827 stock options (SEC Form 4)
4 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
All VYNE newsWhen does VYNE Therapeutics report earnings?
VYNE Therapeutics last reported on Nov 10, 2021, the date it announced on Oct 28, 2021. Before that it reported on Aug 12, 2021.
VYNE earnings historyLatest news
25 items- INSIDERChief Development Officer Payton Lori was granted 99,827 stock options (SEC Form 4)4 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERChief Operating Officer Alford Rachael was granted 89,844 stock options (SEC Form 4)4 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERChief Executive Officer Frey Rebecca was granted 465,857 stock options (SEC Form 4)4 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERChief Medical Officer Ryder Steven was granted 113,137 stock options (SEC Form 4)4 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERChief Financial Officer Zeronda Tyler was granted 156,115 stock options (SEC Form 4)4 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- SECVYNE Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Yarrow Bioscience, Inc. (0001566044) (Filer)
- SECSEC Form 424B5 filed by VYNE Therapeutics Inc.424B5 - Yarrow Bioscience, Inc. (0001566044) (Filer)
- SECSEC Form 424B5 filed by VYNE Therapeutics Inc.424B5 - Yarrow Bioscience, Inc. (0001566044) (Filer)
- SECVYNE Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Yarrow Bioscience, Inc. (0001566044) (Filer)
- SECSEC Form EFFECT filed by VYNE Therapeutics Inc.EFFECT - Yarrow Bioscience, Inc. (0001566044) (Filer)
- SECSEC Form POS AM filed by VYNE Therapeutics Inc.POS AM - Yarrow Bioscience, Inc. (0001566044) (Filer)
- SECAmendment: VYNE Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Regulation FD Disclosure8-K/A - Yarrow Bioscience, Inc. (0001566044) (Filer)
- SECSEC Form 10-Q filed by VYNE Therapeutics Inc.10-Q - Yarrow Bioscience, Inc. (0001566044) (Filer)
- SECSEC Form SCHEDULE 13G filed by VYNE Therapeutics Inc.SCHEDULE 13G - Yarrow Bioscience, Inc. (0001566044) (Subject)
- SECSEC Form SCHEDULE 13D filed by VYNE Therapeutics Inc.SCHEDULE 13D - Yarrow Bioscience, Inc. (0001566044) (Subject)
- SECSEC Form SCHEDULE 13G filed by VYNE Therapeutics Inc.SCHEDULE 13G - Yarrow Bioscience, Inc. (0001566044) (Subject)
- INSIDERLarge owner Rtw Fund Group Gp, Llc disposed of 133,290 shares (SEC Form 4)4 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- SECSEC Form 8-K filed by VYNE Therapeutics Inc.8-K - Yarrow Bioscience, Inc. (0001566044) (Filer)
- INSIDERNew insider Rtw Fund Group Gp, Llc claimed ownership of 399,597 shares (SEC Form 3)3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERSEC Form 4 filed by Director Ashiya Mona4 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERSEC Form 4 filed by Director Zeronda Tyler4 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERNew insider Orbimed Advisors Llc claimed ownership of 266,306 shares (SEC Form 3)3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERNew insider Ashiya Mona claimed ownership of 266,306 shares (SEC Form 3)3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERSEC Form 3 filed by new insider White William Richard3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
- INSIDERSEC Form 3 filed by new insider Silverman Peter B.3 - Yarrow Bioscience, Inc. (0001566044) (Issuer)
News · 26 weeks54+100%
2026-05-242026-11-15
Mix990d
- Insider5(56%)
- SEC Filings4(44%)
Activity · 52 weeks7936 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
VYNE Therapeutics Inc. (VYNE) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for VYNE, including 5 insider trades. The most recent was published Oct 30, 2026.
VYNE FAQ
7 questionsWhat does VYNE Therapeutics Inc. do?
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib...Where does VYNE stock trade?
VYNE Therapeutics Inc. (VYNE) is listed on NASDAQ.What sector and industry is VYNE in?
VYNE Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did VYNE Therapeutics Inc. go public?
VYNE Therapeutics Inc. (VYNE) completed its IPO in 2018.What are analysts saying about VYNE?
Across the last 3 analyst actions on VYNE Therapeutics Inc., there were 0 upgrades and 1 downgrade. The most recent action was from BTIG Research: Neutral on 2025-07-31. Recent price targets range from $7.00 to $8.00.What companies are similar to VYNE?
Notable peers in the same industry include ABT (Abbott Laboratories), JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S). Compare VYNE side-by-side with any of them on Quantisnow.How can I track VYNE on Quantisnow?
Quantisnow aggregates VYNE Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VYNE to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change